TGRX-326 Phase I/II Pharmacokinetic Study - Trial NCT06304805
Access comprehensive clinical trial information for NCT06304805 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shenzhen TargetRx, Inc. and is currently Completed. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shenzhen TargetRx, Inc.
Timeline & Enrollment
Phase 1
Dec 13, 2023
Jan 19, 2024
Primary Outcome
Plasma Cmax,Plasma AUC(0-t),Plasma AUC(0-inf)
Summary
A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of
 TGRX-326 and the effect of different drug specifications on human bioavailability for
 TGRX-326, a drug indicated for non-small cell lung cancer treatment
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06304805
Non-Device Trial